Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OLANZAPINE Cause Product prescribing issue? 52 Reports in FDA Database

Sharpen Your Memory & Focus Naturally

NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.

Boost Your Brain

According to the FDA Adverse Event Reporting System (FAERS), 52 reports of Product prescribing issue have been filed in association with OLANZAPINE (Olanzapine). This represents 0.1% of all adverse event reports for OLANZAPINE.

52
Reports of Product prescribing issue with OLANZAPINE
0.1%
of all OLANZAPINE reports
10
Deaths
12
Hospitalizations

How Dangerous Is Product prescribing issue From OLANZAPINE?

Of the 52 reports, 10 (19.2%) resulted in death, 12 (23.1%) required hospitalization, and 2 (3.8%) were considered life-threatening.

Is Product prescribing issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OLANZAPINE. However, 52 reports have been filed with the FAERS database.

What Other Side Effects Does OLANZAPINE Cause?

Drug ineffective (5,139) Weight increased (3,588) Off label use (3,256) Toxicity to various agents (3,175) Somnolence (2,612) Sedation (2,130) Suicide attempt (2,116) Confusional state (1,898) Condition aggravated (1,810) Overdose (1,765)

What Other Drugs Cause Product prescribing issue?

DUPILUMAB (1,715) POLYETHYLENE GLYCOL 3350 (1,439) LENALIDOMIDE (948) OXYCODONE (646) RIVAROXABAN (359) ACETAMINOPHEN\OXYCODONE (347) ETONOGESTREL (311) ACETAMINOPHEN\HYDROCODONE (298) CERTOLIZUMAB PEGOL (297) CABOZANTINIB S-MALATE (294)

Which OLANZAPINE Alternatives Have Lower Product prescribing issue Risk?

OLANZAPINE vs OLANZAPINE\SAMIDORPHAN L-MALATE OLANZAPINE vs OLAPARIB OLANZAPINE vs OLARATUMAB OLANZAPINE vs OLECLUMAB OLANZAPINE vs OLIVE OIL\SOYBEAN OIL

Related Pages

OLANZAPINE Full Profile All Product prescribing issue Reports All Drugs Causing Product prescribing issue OLANZAPINE Demographics